Two Sigma Advisers
RLMD icon

Two Sigma Advisers’s Relmada Therapeutics RLMD Stock Holding History

Two Sigma Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-162,200
Closed -$783K – 1703
2025
Q4 		$783K Buy
162,200
+123,400
+318% +$413K ﹤0.01% 1605
2025
Q3 		$78K Buy
38,800
+13,700
+55% +$13.1K ﹤0.01% 2245
2025
Q2 		$15.1K Sell
25,100
-262,900
-91% -$135K ﹤0.01% 2292
2025
Q1 		$77.8K Buy
288,000
+89,100
+45% +$29.5K ﹤0.01% 2272
2024
Q4 		$103K Sell
198,900
-43,600
-18% -$106K ﹤0.01% 2217
2024
Q3 		$786K Sell
242,500
-50,000
-17% -$162K ﹤0.01% 1520
2024
Q2 		$878K Sell
292,500
-33,700
-10% -$122K ﹤0.01% 1615
2024
Q1 		$1.52M Sell
326,200
-2,100
-0.6% -$10.1K ﹤0.01% 1367
2023
Q4 		$1.36M Buy
328,300
+163,900
+100% +$485K ﹤0.01% 1480
2023
Q3 		$493K Sell
164,400
-81,300
-33% -$241K ﹤0.01% 1797
2023
Q2 		$604K Sell
245,700
-111,900
-31% -$309K ﹤0.01% 1742
2023
Q1 		$808K Buy
357,600
+34,500
+11% +$119K ﹤0.01% 1738
2022
Q4 		$1.13M Buy
323,100
+301,600
+1,403% +$2.65M ﹤0.01% 1519
2022
Q3 		$796K Buy
+21,500
New +$596K ﹤0.01% 1640

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Two Sigma Advisers's RLMD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 162,200 shares — an estimated $783K sold.

Two Sigma Advisers first reported a position in RLMD in Q3 2022 and held it in 14 quarters. The position peaked at $1.52M in Q1 2024. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Two Sigma Advisers reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 162,200 Relmada Therapeutics shares in Q1 2026, an estimated $783K.
  • Two Sigma Advisers first reported a position in Relmada Therapeutics in Q3 2022 and held it in 14 quarters.
  • Two Sigma Advisers's Relmada Therapeutics position peaked at $1.52M in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.